Synlogic, Inc. (NASDAQ:SYBX – Get Free Report)’s stock price passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $0.84 and traded as high as $1.2050. Synlogic shares last traded at $1.20, with a volume of 1,513 shares trading hands.
Synlogic Stock Up 2.5%
The stock has a market cap of $15.07 million, a price-to-earnings ratio of -4.73 and a beta of 0.48. The stock’s fifty day moving average is $0.85 and its 200-day moving average is $0.71.
Institutional Trading of Synlogic
Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in Synlogic by 116.7% during the fourth quarter. Renaissance Technologies LLC now owns 85,627 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 46,117 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Synlogic in the third quarter worth about $49,000. Finally, DRW Securities LLC acquired a new stake in shares of Synlogic during the fourth quarter worth about $27,000. Institutional investors own 63.40% of the company’s stock.
Synlogic Company Profile
Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
See Also
- Five stocks we like better than Synlogic
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.
